Safety and Efficacy of Liraglutide, 3.0 mg, Once Daily vs Placebo in Patients With Poor Weight Loss Following Metabolic Surgery: The BARI-OPTIMISE Randomized Clinical Trial

IMPORTANCE: Metabolic surgery leads to weight loss and improved health, but these outcomes are highly variable. Poor weight loss is associated with lower circulating levels of glucagon-like peptide-1 (GLP-1). OBJECTIVE: To assess the efficacy and safety of the GLP-1 receptor agonist, liraglutide, 3....

Descripción completa

Detalles Bibliográficos
Autores principales: Mok, Jessica, Adeleke, Mariam O., Brown, Adrian, Magee, Cormac G., Firman, Chloe, Makahamadze, Christwishes, Jassil, Friedrich C., Marvasti, Parastou, Carnemolla, Alisia, Devalia, Kalpana, Fakih, Naim, Elkalaawy, Mohamed, Pucci, Andrea, Jenkinson, Andrew, Adamo, Marco, Omar, Rumana Z., Batterham, Rachel L., Makaronidis, Janine
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Medical Association 2023
Materias:
Original Investigation
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10372755/
https://www.ncbi.nlm.nih.gov/pubmed/37494014
http://dx.doi.org/10.1001/jamasurg.2023.2930

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10372755/
https://www.ncbi.nlm.nih.gov/pubmed/37494014
http://dx.doi.org/10.1001/jamasurg.2023.2930

Ejemplares similares